Tradestie Institutional Equity Comparison Engine

SYRE vs DNTH โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DNTH Overall Edge

DNTH Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Dianthus Therapeutics, Inc. Common Stock (DNTH) driven by superior Growth & Margin, Options & Structure while SYRE counters with relative strength in Momentum & Technical. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DNTH at N/M Forward P/E and -8683.9% operating margin (+205.6% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against DNTH sits in CONSOLIDATION (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SYRE N/M vs DNTH N/M Fwd P/E
Growth & Margin Winner DNTH
Op Margin 0.0% vs -8683.9% ยท YoY +0.0% vs +205.6%
Momentum & Technical Winner SYRE
1Y +341.7% vs +149.5% ยท 52W Pos 88% vs 65%
Options & Structure Winner DNTH
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (7th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
DNTH NASDAQ
Dianthus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$88.58
-3.52% 1D
Market Cap $5.2B
1M Return +22.87%
1Y Return +149.51%
Forward P/E N/M
Unified AI Score
34.1 / 100 SELL
Tech 8.0 Fund 43.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% DNTH +149.51% Spread: +192.23 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% DNTH TTM Op. Margin: -8683.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs DNTH. Trailing 12-month operating profitability (SYRE 0.0% vs DNTH -8683.9%) and valuation multiples (SYRE N/M vs DNTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (4) vs DNTH (3)
Institutional Metric SYRE DNTH Criterion Row Winner
Market Capitalization Scale $9.8B $5.2B Larger Scale SYRE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +205.6% Higher Growth DNTH
Operating Margin (TTM) Profitability 0.0% -8683.9% Higher Margin SYRE
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -35.0% -22.6% Higher ROE DNTH
52-Week Range Position Momentum 88% ($22โ€“$111) 65% ($34โ€“$118) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 1.03ฮฒ ยท 41% Vol Lower Realized Risk DNTH
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 34.1 / 100 (SELL) Higher Composite SYRE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs DNTH Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DNTH CONSOLIDATION
149d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live DNTH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor DNTH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.